Deltagen (OTCPK:DGEN) - Stock Price, News & Analysis

DGEN Stock Overview

Provides drug discovery tools and services to the biopharmaceutical industry. More details

DGEN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($32)

Latest financial reports are more than a year old

Deltagen Inc. Competitors

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

DermTech

OTCPK:DMTK.Q

US$35.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

Price History & Performance

Summary of all time highs, changes and price drops for Deltagen
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.00%
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	DGEN	US Life Sciences	US Market
7D	0%	3.9%	1.6%
1Y	n/a	4.7%	32.3%

Return vs Industry: Insufficient data to determine how DGEN performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how DGEN performed against the US Market.

Price Volatility

Is DGEN's price volatile compared to industry and market?
DGEN volatility
DGEN Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: DGEN has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DGEN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Robert Driscoll	www.deltagen.com

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases.

Deltagen Inc. Fundamentals Summary

How do Deltagen's earnings and revenue compare to its market cap?
DGEN fundamental statistics
Market cap	US$32.00
Earnings (TTM)	-US$46.00k
Revenue (TTM)	US$770.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is DGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DGEN income statement (TTM)
Revenue	US$770.00k
Cost of Revenue	US$4.00k
Gross Profit	US$766.00k
Other Expenses	US$812.00k
Earnings	-US$46.00k

Last Reported Earnings

Dec 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did DGEN perform over the long term?

See historical performance and comparison